Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3)
This trial looked at chemotherapy and surgery for women with ovarian cancer that has come back (relapsed). It was supported by Cancer Research UK.
More about this trial
The main treatments for ovarian cancer are surgery and chemotherapy. But sometimes the cancer starts to grow again. Doctors usually treat ovarian cancer that has started to grow again with chemotherapy.
In this trial, doctors were looking at women whose cancer had come back after chemotherapy that included a platinum drug such as carboplatin. They wanted to find out if surgery and chemotherapy is better than chemotherapy alone, for ovarian cancer that has come back.
The aims of this study were to find out:
- if surgery and chemotherapy is better than chemotherapy alone for ovarian cancer that has come back
- more about the side effects
Summary of results
This trial recruited 407 women with ovarian cancer. They’d all had treatment with a platinum chemotherapy drug (such as carboplatin) before, but their cancer had started to grow again.
The women taking part were put into 1 of 2 treatment groups at random, and:
- 204 women had chemotherapy
- 203 women had surgery and then chemotherapy
The research team looked at how long it was before the cancer started to grow again. They found it was:
- 14 months for those who had chemotherapy
- 20 months for those who had surgery and chemotherapy
When they looked at the side effects, they found they were similar in both groups. A few more women who had chemotherapy alone had a temporary drop in blood cells.
The research team are still following the women who took part in this trial and analysing the results. They hope to release more results in the future, including information about how long the women in both groups lived after joining the trial. We plan to update the information on this page once these results are available.
They concluded that, so far, the results show that surgery and chemotherapy should be an option for ovarian cancer that has come back after treatment.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor David Luesley
Cancer Research UK
Cancer Research UK Clinical Trials Unit Birmingham
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer